April 9 Product Theatres

Note: These presentations are not eligible for CME credits.

  • Retevmo® (selpercatinib)
Retevmo® (selpercatinib)

Retevmo® (selpercatinib) A precision-based therapy for certain RET-driven cancers-Focus on Advanced or Metastatic Thyroid Cancer

Presented by Dr. Todd Frieze

Join us to review the clinical data for LIBRETTO-001, examine the efficacy and safety profiles, and explore the dosing, dose modifications, administration, and appropriate testing methods for a biomarker-driven therapy. This program aims to help you identify patients who may be eligible for this treatment option.


LENVIMA®: A First-Line Treatment for Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Virtual Program, presented on behalf of Eisai Inc.

This satellite symposium will educate HCPs on LENVIMA as a 1L option for treatment of locally recurrent or metastatic, progressive, RAI-R DTC including an overview of the SELECT trial and efficacy data as well as safety profile and strategies to recognize, monitor, and manage adverse reactions (ARs) that may occur with LENVIMA. Attendees will also have the opportunity to review patient case studies and engage in discussion regarding the treatment selection process.
This program is sponsored by Eisai Inc. For more information on LENVIMA, please visit and

Back to Sponsorship

There are outstanding opportunities for industry participation. For more details on the available sponsorship and exhibitor options, please contact:

Rebecca Darling,
Call: +1. 519.263.5050 / +1. 519.263.6001 (direct)
Toll Free: 1.888.527.3434
(North America only)
Cass Bayley
Call: +1. 519.263.5050 / +1. 519.263.6000 (direct)
Toll Free: 1.888.527.3434
(North America only)

Keep in Touch with Us

Join our mailing list to receive the latest updates and get the first look at new content.
© 2022 World Congress on Thyroid Cancer Privacy Policy
Share via
Copy link
Powered by Social Snap